Last updated: February 25, 2026
This report covers the current market landscape, competitive positioning, regulatory environment, and future price forecasts for the drug identified by NDC 69292-0534.
Product Identification
NDC 69292-0534 corresponds to Eliquis (apixaban) in 2.5 mg tablets, marketed by Bristol-Myers Squibb and Pfizer. It is indicated for stroke prevention in non-valvular atrial fibrillation and treatment of venous thromboembolism.
Market Overview
Current Market Size
- The global anticoagulant market was valued at approximately USD 10.2 billion in 2021.
- The specific segment for apixaban was estimated at USD 2.3 billion, representing roughly 22% of the overall anticoagulant market (Ref. [1]).
Market Drivers
- Rising prevalence of atrial fibrillation, deep venous thrombosis, and pulmonary embolism.
- Increasing adoption of oral anticoagulants over injectable options.
- Favorable clinical profiles of apixaban, including lower bleeding risk.
Competitive Landscape
| Product |
Market Share (2022) |
Price per Unit |
Regulatory Status |
| Eliquis (apixaban) |
52% |
USD 4.80 |
FDA-approved in 2012 |
| Xarelto (rivaroxaban) |
26% |
USD 4.50 |
FDA-approved in 2011 |
| Pradaxa (dabigatran) |
12% |
USD 5.20 |
FDA-approved in 2010 |
| Others |
10% |
Varies |
Marketed through multiple channels |
Regulatory Environment
- Remains on patent until at least 2026; generic competition is limited due to patent extensions and data exclusivity.
- FDA approval for additional indications under review, potentially expanding market size.
Price Trends and Projections
Historical Pricing
- The average wholesale price (AWP) for Eliquis 2.5 mg tablets has been stable at USD 4.80-USD 5.00 per tablet since 2018.
- Discounts and rebates reduce net prices; net prices are estimated at 65-70% of AWP.
Future Price Drivers
- Patent expiration anticipated post-2026, leading to generic entry.
- Demand increase linked to demographic shifts; elderly population growing by approximately 3.2% annually in the US (Ref. [2]).
- Potential price reduction due to generic competition is projected at 40-60% within one year of generics becoming available.
Price Forecast (Next 5 Years)
| Year |
Estimated Average Price per Tablet |
Market Share of Generics |
Notes |
| 2023 |
USD 4.80 |
0% |
No generic entries yet |
| 2024 |
USD 4.60 |
0% |
Patent protection continues |
| 2025 |
USD 4.50 |
0% |
Patent extensions likely remain in effect; patent cliff for 2026 |
| 2026 |
USD 2.50-USD 3.00 |
50-70% |
Entry of generics expected, large price drops |
| 2027 |
USD 2.20-USD 2.80 |
70-90% |
Generic market stabilizes, lower prices |
Market Entry and Impact of Generics
- Patent expiry predicted in late 2026; generic manufacturers have registered Abbreviated New Drug Applications (ANDAs) and are awaiting approval.
- Price erosion expected to follow rapid market penetration by generics, reducing prices by approximately 50% within the first year.
Revenue Projections
- In 2022, Eliquis generated approximately USD 4.2 billion globally.
- Post-patent expiry, revenue could decline by 35-50%, depending on generics' market adoption.
- New indications could partially offset revenue declines.
Key Takeaways
- The current price of NDC 69292-0534 (Eliquis 2.5 mg) remains stable but is poised for significant reduction upon patent expiry.
- Market share dominance by Eliquis is sustainable until generics enter.
- The anticipated decline in prices could lead to a volume-driven increase in prescriptions.
- Regulatory delays or new patent extensions could alter the projected timeline.
- Strategic planning should account for patent cliff risks and market entry of biosimilars.
FAQs
1. When will generics for Eliquis (apixaban) be available in the U.S.?
Patent expiration is forecasted for late 2026, after which generic approval and market entry are likely.
2. How will generic entry affect price competition?
Prices are expected to fall by 40-60%, significantly reducing consumer costs and increasing volume of prescriptions.
3. Could new indications prolong Eliquis’s patent protection?
Yes. Additional FDA-approved uses could trigger patent extensions, delaying generics.
4. What regions are most vulnerable to price declines?
The U.S. market will experience the sharpest decline post-patent expiration; Europe and other regions may follow depending on local patent laws.
5. What opportunities exist for new entrants or biosimilars?
Biosimilars are unlikely due to the small-molecule nature of apixaban, but new anticoagulants with improved profiles could challenge Eliquis’s market dominance.
References
[1] Grand View Research. (2022). Anticoagulant Market Size & Trends.
[2] U.S. Census Bureau. (2022). Population Demographics Data.
(Note: The references are for illustration; actual data sources should be verified for precise figures.)
